School of Medicine, Faculty of Health Sciences, Queen's University, 15 Arch St, Kingston, ON, K7L 3N6, Canada.
Neural Engineering & Therapeutics Team, Toronto Rehabilitation Institute, University Health Network, 550 University Ave, Toronto, Canada.
BMC Palliat Care. 2020 Mar 23;19(1):35. doi: 10.1186/s12904-020-0538-y.
Socioeconomic inequalities in access to, and utilization of medical care have been shown in many jurisdictions. However, the extent to which they exist at end-of-life (EOL) remains unclear.
Studies in MEDLINE, EMBASE, CINAHL, ProQuest, Web of Science, Web of Knowledge, and OpenGrey databases were searched through December 2019 with hand-searching of in-text citations. No publication date or language limitations were set. Studies assessing SES (e.g. income) in adults, correlated to EOL costs in last year(s) or month(s) of life were selected. Two independent reviewers performed data abstraction and quality assessment, with inconsistencies resolved by consensus.
A total of twenty articles met eligibility criteria. Two meta-analyses were performed on studies that examined total costs in last year of life - the first examined costs without adjustments for confounders (n = 4), the second examined costs that adjusted for confounders, including comorbidities (n = 2). Among studies which did not adjust for comorbidities, SES was positively correlated with EOL costs (standardized mean difference, 0.13 [95% confidence interval, 0.03 to 0.24]). However, among studies adjusting for comorbidities, SES was inversely correlated with EOL expenditures (regression coefficient, -$150.94 [95% confidence interval, -$177.69 to -$124.19], 2015 United States Dollars (USD)). Higher ambulatory care and drug expenditure were consistently found among higher SES patients irrespective of whether or not comorbidity adjustment was employed.
Overall, an inequality leading to higher end-of-life expenditure for higher SES patients existed to varying extents, even within countries providing universal health care, with greatest differences seen for outpatient and prescription drug costs. The magnitude and directionality of the relationship in part depended on whether comorbidity risk-adjustment methodology was employed.
在许多司法管辖区,已经发现社会经济地位不平等会影响医疗保健的获取和利用。然而,在生命末期(EOL),这种不平等的程度尚不清楚。
通过对 MEDLINE、EMBASE、CINAHL、ProQuest、Web of Science、Web of Knowledge 和 OpenGrey 数据库进行搜索,并对文中的参考文献进行手工搜索,检索时间截至 2019 年 12 月。没有设置发表日期或语言限制。选择评估 SES(例如收入)的成年人,并将其与生命最后一年或几个月的 EOL 成本相关的研究。由两名独立的审查员进行数据提取和质量评估,通过共识解决不一致的地方。
共有二十篇文章符合入选标准。对研究生命最后一年总费用的两项荟萃分析 - 第一项分析未调整混杂因素的费用(n = 4),第二项分析调整混杂因素(包括合并症)的费用(n = 2)。在未调整合并症的研究中,SES 与 EOL 费用呈正相关(标准化均数差,0.13 [95%置信区间,0.03 至 0.24])。然而,在调整合并症的研究中,SES 与 EOL 支出呈负相关(回归系数,-$150.94 [95%置信区间,-$177.69 至 -$124.19],2015 年美元)。无论是否进行合并症调整,SES 较高的患者的门诊和药物支出始终较高。
总体而言,即使在提供全民医疗保健的国家,SES 较高的患者的 EOL 支出也存在不平等,程度不同,差异最大的是门诊和处方药费用。这种关系的大小和方向在一定程度上取决于是否采用合并症风险调整方法。